GRCE

Grace Therapeutics, Inc. (ticker: GRCE) is an NASDAQ-listed pharma company. DredgeCap's structured extraction of GRCE's SEC filings surfaces 2 active risk signals, including 2 auditor-change signals. GRCE reported $100.00M in revenue and -$6.62M for the period ending 2022-03-31, with operating cash flow of -$7.17M. Cash and equivalents stood at $18.67M (up 68.9% year-over-year). Total assets of $68.49M exceed total liabilities of $3.60M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.